三阴性乳腺癌预后生物标志物研究新进展  

New Advances in Prognostic Biomarker of Triple-Negative Breast Cancer

作　　者：曹钰 贾存东[1] 

机构地区：[1]新疆医科大学第三临床医学院,新疆 乌鲁木齐

出　　处：《临床医学进展》2023年第11期17000-17005,共6页Advances in Clinical Medicine

摘　　要：三阴性乳腺癌(triple-negative breast cancer, TNBC)与其他乳腺癌亚型相比,化疗是其主要的治疗方式,化疗导致的毒副作用以及耐药性使得TNBC患者的远期预后不容乐观。这种情况进一步鼓励接受生物标志物作为有效和精确的TNBC治疗的一些靶向部分迫在眉睫。在本综述中,我们旨在讨论TNBC以及相关的新兴和已批准疗法中已建立和开发的预后和预测生物标志物的最新进展。Compared with other subtypes of breast cancer, chemotherapy is the main treatment for triple negative breast cancer (TNBC). The long-term prognosis of TNBC patients is not optimistic due to the toxic side effects and drug resistance caused by chemotherapy. This situation further encour-ages the acceptance of biomarkers as effective and precise targeting components for TNBC treat-ment, which is urgent. In this review, we aim to discuss the latest advances in established and de-veloped prognostic and predictive biomarkers in TNBC and related emerging and approved thera-pies.

关 键 词：三阴性乳腺癌 预后标志物 危险因素 治疗靶点 

分 类 号：R73[医药卫生—肿瘤]